<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133809</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00041120</org_study_id>
    <secondary_id>10402</secondary_id>
    <nct_id>NCT00133809</nct_id>
  </id_info>
  <brief_title>Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetes Using the Edmonton Protocol of Steroid Free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the ability of islet transplantation to restore glycemic control and
      achieve insulin independence in type 1 diabetic subjects with life-threatening hypoglycemia
      and unawareness, or recurrent hyperglycemia with ketoacidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LAY SUMMARY:

      More than 1 million North Americans have type 1 diabetes. Each year, approximately 30,000 new
      cases of type 1 diabetes are diagnosed in the United States. Type 1 diabetes destroys islets,
      a cluster of cells within the pancreas that produce insulin. Insulin is a hormone with many
      effects. However, the most important effect of insulin is to control the level of sugar in
      the blood. People with Type 1 diabetes no longer produce insulin and must take insulin
      injections to live. Despite steady improvements in the management of this disease, its
      victims remain at increased risk for stroke, heart attack, kidney failure, amputation,
      blindness, nerve damage and premature death. The life expectancy of a teenager is reduced by
      thirty years from the time of onset of the disease. Unfortunately, many type 1 diabetics
      cannot control their blood sugars in spite of very careful monitoring and the frequent
      injection of insulin. This group of patients is considered to have labile or &quot;brittle&quot;
      diabetes. These &quot;brittle&quot; diabetics can often have wide swings in their blood sugar levels
      that can be life threatening. Hypoglycemia, or low blood sugars, occurs when too much insulin
      is in the bloodstream. When this occurs, it is vital that patients eat or drink something
      right away that will increase their blood sugars. Many diabetics lose the ability to
      recognize when their blood sugars are getting dangerously low. These episodes of hypoglycemia
      can lead to coma, and possibly death, if not recognized and treated right away. Patients can
      also experience extreme increases in blood sugars, or hyperglycemia, as a result of emotional
      or physical stress. Hyperglycemia can result in dehydration, confusion, and a condition
      called ketoacidosis, which can lead to death. When this happens, insulin must be given as
      soon as possible.

      Islet transplantation can restore the body's ability to make insulin and, in turn, restore
      normal blood sugar levels.

      Since the 1960's, doctors and scientists have attempted to replace this islet function by
      performing whole organ pancreas transplantation. While the results of pancreas
      transplantation have improved dramatically in recent years, this approach has largely been
      limited to patients with kidney disease who have also needed a kidney transplant. This is
      because of the risks associated with the surgical procedure and the immunosuppressive drugs
      required to prevent rejection or the destruction of the transplanted pancreas by the body's
      immune system. Transplantation of a whole pancreas requires a major operation that is done
      through an incision in the abdomen. The patient must be under general anesthesia, or asleep,
      for the entire procedure. Recent clinical experience suggests that islet transplantation may
      be a useful approach to correct diabetes in humans.

      Islet transplantation offers a direct approach to the treatment of type 1 diabetes. A large
      number of experimental studies carried out in many laboratories over the last decade have
      documented the beneficial effects of islet transplants in experimental animals. These
      experiments have confirmed both the efficiency and safety of islet transplantation.

      The inability to isolate enough islets from a single pancreas has been one obstacle to
      successful islet transplantation. A certain number of islets must be isolated, or separated,
      from a single pancreas in order to use them for transplant. If this minimum number of islets
      is not obtained, then the islets do not effectively reverse diabetes. Progress in isolating
      the islets from a human pancreas has been dramatic in the last several years. Advances in
      equipment and technology have lead to increases in the number of islets that can be isolated
      from a single pancreas.

      After successful isolation, the islets can be injected through a catheter into the patient's
      liver during a thirty-minute procedure. A group of doctors at the University of Alberta in
      Edmonton, Canada has had promising results in human islet transplantation. Normal sugar
      levels have been documented after human islet transplants. Also, recent improvements in
      immunosuppressive drug treatments have resulted in sustained insulin-independence in selected
      type 1 diabetic patients. The traditional method of transplant immunosuppression includes
      using some form of a steroid drug. Steroids have been found to injure or kill the islets
      after transplant. The doctors in Edmonton, Canada established an immunosuppression formula
      that does not use steroids. The objective of the study here at Emory University is to
      reproduce the successful results of human islet transplantation that have been achieved by
      the doctors at the University of Alberta using steroid free immunosuppression.

      The Emory Islet Transplant Program will enroll ten patients, ages 18 to 65, in the study.
      Each of the ten patients will receive at least 2 islet transplants from 2 different organ
      donors. A third transplant may be required based on the patient's insulin requirements after
      the 1st two transplants. Each patient will be placed on immunosuppressive drugs to prevent
      the body from rejecting or destroying the transplanted islets. Each patient will have his/her
      blood sugar levels and insulin requirements monitored very closely after each transplant. The
      patients will also have various tests to determine if their diabetic complications improve,
      remain the same, or become worse. The patients will be asked to record any episodes of
      hypoglycemia or low blood sugars while participating in this study. Emory will examine
      whether or not there is a decrease in how often the episodes occur. Patients will also
      undergo regular eye exams to document retinal changes or improvements that may occur after
      transplant. At this time it is not known whether islet transplantation slows or stops the
      progression of common diabetic complications. More experience and research is needed before
      this can be determined. One focus of our research will be to study diabetic complications in
      patients who receive islet transplants.

      The major goal of the Emory Islet Transplant Program is for patients participating in this
      study to be free of the need for insulin injections after 2 islet transplants. Because many
      advances have been made in islet transplantation, the transplant team at Emory would like to
      participate in this promising treatment of type 1 diabetes and, most importantly, help those
      who suffer from this disease become free from daily insulin injections and avoid the
      devastating complications that happen as a result of diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation</measure>
    <time_frame>one year after transplant</time_frame>
    <description>Independence from insulin injections is measured by the actual use of insulin by the study participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Insulin-independent Subjects Following Islet Transplantation</measure>
    <time_frame>1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation</time_frame>
    <description>Participants who did not need to take insulin at 1, 3, 6, 12, 18, 24, 36, 48 and 60 months following islet transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With HbA1C ≤ 6.5%</measure>
    <time_frame>1, 3, 6, 9,12,18,24, 36, 48 and 60 months post-transplantation</time_frame>
    <description>HbA1C was assessed in subjects 1, 3, 6, 9,12,18,24, 36, 48 and 60 months after transplantation and the number of subjects with values ≤ 6.5% was recorded which indicated better control of blood glucose levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL</measure>
    <time_frame>1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation</time_frame>
    <description>Number of Participants With Endogenous Insulin Production Post-transplant, Assessed by Fasting C-peptide Levels at 1, 3, 6, 9,12,18, 24, 36, 48 and 60 months after islet cell transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Islet Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplantation of Human Islets</intervention_name>
    <description>Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
    <arm_group_label>Islet Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus diagnosed &gt; 5 years previously

          -  Body mass index less than or equal to 26

          -  18 to 65 years of age

          -  Compliance with an optimized diabetic management plan as assessed by an Emory
             University endocrinologist

          -  Checking and recording blood sugars at least 3 times per day

          -  Intensive insulin therapy (injecting insulin at least 3 times a day or using an
             insulin pump)

          -  Severe hypoglycemia and/or hyperglycemia. Severe hypoglycemia is defined by: episodes
             requiring assistance by others and/or hypoglycemic unawareness (the inability to
             recognize blood glucose &lt; 54 mg/dL). Severe hyperglycemia is defined by: two episodes
             of ketoacidosis requiring hospitalization within the past year.

        Exclusion Criteria:

          -  Renal dysfunction

          -  Severe co-existing cardiac disease, characterized by any one of these conditions:
             recent myocardial infarction (within past six months); angiographic evidence of
             non-correctable coronary artery disease; or evidence of ischemia on a dobutamine
             stress echocardiogram.

          -  Current bacterial or fungal infection

          -  Macroproteinuria

          -  Baseline hemoglobin &lt; 11.4 gm/dL in women; &lt; 12.9 gm/dL in men.

          -  Hyperlipidemia

          -  Positive tests for human immunodeficiency virus (HIV), or hepatitis B or C

          -  Negative antibody test for varicella zoster virus (subjects may be reconsidered if
             they receive the vaccination and convert to a positive antibody)

          -  History of malignancy (except squamous or basal cell skin carcinoma)

          -  Previous/concurrent organ transplantation

          -  Presence of HLA panel reactive antibodies &gt; 20%

          -  Active peptic ulcer disease

          -  Evidence of gallbladder disease including cholecystitis and cholelithiasis

          -  Evidence of liver disease including hepatic neoplasm, portal hypertension, or
             persistently abnormal liver function tests.

          -  Persistent coagulopathy or current use of anticoagulants (not including aspirin)

          -  Sickle cell anemia

          -  Positive pregnancy test, intent for future pregnancy, failure to follow effective
             contraceptive measures, or presently breastfeeding

          -  Active alcohol or substance abuse. This includes smoking (must be abstinent for six
             months). Active alcohol abuse should be considered using the current National
             Institute on Alcohol Abuse and Alcoholism (NIAAA) definitions.

          -  Psychiatric disorder making the subject not a suitable candidate for transplantation

          -  Current use of systemic steroid medications

          -  Evidence of insulin resistance (insulin requirement &gt; 1.2 units/kg/day)

          -  Inability to provide informed consent

          -  Any condition or any circumstance that makes it unsafe to undergo an islet transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole A Turgeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian P. Larsen, MD DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Emory Transplant Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jdrf.org</url>
    <description>Juvenile Diabetes Research Foundation, non-profit organization, sponsor of this study</description>
  </link>
  <link>
    <url>http://transplant.emory.edu/index.html</url>
    <description>Emory Transplant Center website</description>
  </link>
  <results_reference>
    <citation>Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, Adams AB, Sears MH, Bowen PH, Kirk AD, Pearson TC, Larsen CP. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010 Sep;10(9):2082-91. doi: 10.1111/j.1600-6143.2010.03212.x.</citation>
    <PMID>20883542</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <results_first_submitted>April 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2016</results_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Nicole Turgeon MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Islet Transplantation</keyword>
  <keyword>Immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ten participants fulfilled entry criteria and were listed for islet transplantation. Prior to receiving the transplant, one of the participants became ineligible while on the organ donor waiting list due to glucose control being stabilized with an insulin pump, and an additional participant was lost to follow up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplant</title>
          <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible participants who received islet transplantation</population>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplant</title>
          <description>10 subjects were found eligible and were can be matched to an appropriate donor will receive/have received an islet transplant---1 INELIGIBLE WHILE ON WAITLIST.
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation</title>
        <description>Independence from insulin injections is measured by the actual use of insulin by the study participants.</description>
        <time_frame>one year after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation</title>
          <description>Independence from insulin injections is measured by the actual use of insulin by the study participants.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Insulin-independent Subjects Following Islet Transplantation</title>
        <description>Participants who did not need to take insulin at 1, 3, 6, 12, 18, 24, 36, 48 and 60 months following islet transplantation</description>
        <time_frame>1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Insulin-independent Subjects Following Islet Transplantation</title>
          <description>Participants who did not need to take insulin at 1, 3, 6, 12, 18, 24, 36, 48 and 60 months following islet transplantation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With HbA1C ≤ 6.5%</title>
        <description>HbA1C was assessed in subjects 1, 3, 6, 9,12,18,24, 36, 48 and 60 months after transplantation and the number of subjects with values ≤ 6.5% was recorded which indicated better control of blood glucose levels.</description>
        <time_frame>1, 3, 6, 9,12,18,24, 36, 48 and 60 months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HbA1C ≤ 6.5%</title>
          <description>HbA1C was assessed in subjects 1, 3, 6, 9,12,18,24, 36, 48 and 60 months after transplantation and the number of subjects with values ≤ 6.5% was recorded which indicated better control of blood glucose levels.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL</title>
        <description>Number of Participants With Endogenous Insulin Production Post-transplant, Assessed by Fasting C-peptide Levels at 1, 3, 6, 9,12,18, 24, 36, 48 and 60 months after islet cell transplantation</description>
        <time_frame>1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL</title>
          <description>Number of Participants With Endogenous Insulin Production Post-transplant, Assessed by Fasting C-peptide Levels at 1, 3, 6, 9,12,18, 24, 36, 48 and 60 months after islet cell transplantation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months Post-Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for as long as the study participants were willing to be followed for safety monitoring. The follow up time ranged from 3 years to 5 years and 9 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplant</title>
          <description>All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
Transplantation of Human Islets: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for diarrhea, nausea, vomiting, and abdominal pain</sub_title>
                <description>Hospitalization for diarrhea, nausea, vomiting, and abdominal pain management</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pneumonia with bilateral pleural effusions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth Ulcers</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicole Turgeon MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-727-3257</phone>
      <email>nturgeo@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

